BioCentury | Feb 3, 2017
Company News

Pro Bono Bio, Spero deal

...Spero acquired multiple antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab Anti...
...of Gram-negative pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii . Pro Bono Bio...
...to inquiries. Pro Bono Bio Group Ltd., London, U.K. Spero Therapeutics LLC , Cambridge, Mass. Business: Infectious Nora Weintraub Pro Bono Bio Group plc Spero...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 17, 2012
Company News

PolyTherics, Pro Bono Bio deal

...to develop and commercialize a pegylated, longer-acting version of Factor VIII using PolyTherics' TheraPEG technology. Pro Bono Bio...
...for development and regulatory milestones, plus royalties on worldwide sales. Under the expanded 2009 deal, Pro Bono Bio...
...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...
BioCentury | Jun 4, 2012
Company News

PolyTherics, Pro Bono Bio deal

...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...
...further development. The partners also began a feasibility study to develop a pegylated Factor VIII. Pro Bono Bio...
...worldwide rights to develop the product. Details were not disclosed. PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Oct 31, 2011
Finance

Finding love in Russia

...& Flow. Portfolio companies include oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI); inflammation and dermatology company Pro Bono Bio...
BioCentury | Sep 19, 2011
Company News

Pro Bono Bio sales and marketing update

...pain in the knee. The company said price will depend on the joint receiving treatment. Pro Bono Bio...
...physically sequester arachidonic acid, preventing its conversion to prostaglandin mediators involved in pain and inflammation. Pro Bono Bio...
...inflammatory skin disorders, including psoriasis and eczema, in 1Q12 and by year end 2011, respectively. Pro Bono Bio...
BioCentury | Sep 19, 2011
Finance

Celtic rolls its own

...its funds - about $700 million in all - into a single company. The newco, Pro Bono Bio...
BioCentury | Sep 13, 2011
Company News

Celtic Pharma, RUSNANO form nanotech-based newco

...The Russian Corp. of Nanotechnologies and Celtic Pharma Holdings launched Pro Bono Bio , a newco developing products...
Items per page:
1 - 10 of 10
BioCentury | Feb 3, 2017
Company News

Pro Bono Bio, Spero deal

...Spero acquired multiple antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab Anti...
...of Gram-negative pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii . Pro Bono Bio...
...to inquiries. Pro Bono Bio Group Ltd., London, U.K. Spero Therapeutics LLC , Cambridge, Mass. Business: Infectious Nora Weintraub Pro Bono Bio Group plc Spero...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 24, 2012
Clinical News

PolyTherics, Pro Bono Bio preclinical data

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Sep 17, 2012
Company News

PolyTherics, Pro Bono Bio deal

...to develop and commercialize a pegylated, longer-acting version of Factor VIII using PolyTherics' TheraPEG technology. Pro Bono Bio...
...for development and regulatory milestones, plus royalties on worldwide sales. Under the expanded 2009 deal, Pro Bono Bio...
...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...
BioCentury | Jun 4, 2012
Company News

PolyTherics, Pro Bono Bio deal

...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...
...further development. The partners also began a feasibility study to develop a pegylated Factor VIII. Pro Bono Bio...
...worldwide rights to develop the product. Details were not disclosed. PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...
BioCentury | Oct 31, 2011
Finance

Finding love in Russia

...& Flow. Portfolio companies include oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI); inflammation and dermatology company Pro Bono Bio...
BioCentury | Sep 19, 2011
Company News

Pro Bono Bio sales and marketing update

...pain in the knee. The company said price will depend on the joint receiving treatment. Pro Bono Bio...
...physically sequester arachidonic acid, preventing its conversion to prostaglandin mediators involved in pain and inflammation. Pro Bono Bio...
...inflammatory skin disorders, including psoriasis and eczema, in 1Q12 and by year end 2011, respectively. Pro Bono Bio...
BioCentury | Sep 19, 2011
Finance

Celtic rolls its own

...its funds - about $700 million in all - into a single company. The newco, Pro Bono Bio...
BioCentury | Sep 13, 2011
Company News

Celtic Pharma, RUSNANO form nanotech-based newco

...The Russian Corp. of Nanotechnologies and Celtic Pharma Holdings launched Pro Bono Bio , a newco developing products...
Items per page:
1 - 10 of 10